Ayala Partnering with Novartis on Investigational AL102 for Treatment of Multiple Myeloma
In a new agreement, Ayala Pharmaceuticals will work…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Revlimid Maintenance Extends Survival Without Disease Worsening in Myeloma Patients, Phase 3 Trial Shows
Long-term maintenance treatment with Revlimid (lenalidomide) significantly improves…
First Patient Treated with Phase 1 Trial Combo of Reolysin, Opdivo, and Kyprolis
A Phase 1 trial of the combination of…
Study Tracing Myeloma Progression from Precursor Conditions Seeks Participants
A study is recruiting participants to examine the molecular…
Janssen Seeks Darzalex Approval for Certain Newly Diagnosed Multiple Myeloma Patients in Japan
Janssen Pharmaceutical has submitted an application to Japanese authorities requesting…
Split Dosing Regimen of Darzalex Approved in Europe for Multiple Myeloma Patients
The European Commission has approved a new dosing regimen…
